Table 2 Mean urinary (±SD) concentrations of biomarkers assessed by Multi-Array and commercial ELISA assays in cohort #1
From: A multiplex immunoassay for the non-invasive detection of bladder cancer
Multi-Array® | Commercial ELISA | |||||
|---|---|---|---|---|---|---|
Total bladder cancer (n = 29) | Total controls (n = 33) | p value | Total bladder cancer (n = 29) | Total controls (n = 33) | p value | |
IL8 (pg/ml) | 1429.3 ± 2897.7 | 123.1 ± 510.2 | <0.0001 | 1155.7 ± 2179.7 | 33.3 ± 45.1 | <0.0001 |
MMP9 (ng/ml) | 24.4 ± 64.2 | 3.2 ± 10.6 | <0.0001 | 4.8 ± 4.1 | 0.9 ± 1.4 | <0.00001 |
A1AT (ng/ml) | 4968.0 ± 8965.9 | 412.9 ± 513.9 | 0.0004 | 2362.2 ± 3682.4 | 218.8 ± 593.6 | <0.0001 |
ANG (pg/ml) | 8487.6 ± 25,979.1 | 816.3 ± 947.4 | 0.004 | 538.5 ± 863.9 | 174.0 ± 210.8 | 0.016 |
VEGFA (pg/ml) | 357.7 ± 437.6 | 306.7 ± 467.9 | 0.481 | 294.5 ± 795.4 | 166.3 ± 137.5 | 0.631 |
CA9 (pg/ml) | 35.9 ± 63.6 | 15.4 ± 22.6 | 0.828 | 2.3 ± 0.0 | 2.3 ± 0.0 | 1.000 |
MMP10 (pg/ml) | 112.7 ± 196.9 | 26.1 ± 64.8 | 0.002 | 12.2 ± 43.7 | 4.1 ± 0.0 | 0.301 |
APOE (pg/ml) | 210,368.9 ± 758,136.6 | 7316.1 ± 11,258.8 | 0.016 | 46,241.4 ± 38,121.7 | 30,000.0 ± 0.0 | 0.001 |
PAI1 (ng/ml) | 5.2 ± 13.7 | 0.2 ± 1.0 | <0.0001 | 0.1 ± 0.1 | 0.1 ± 0.0 | 0.065 |
SDC1 (pg/ml) | 10,393.9 ± 12,279.5 | 13,477.3 ± 10,745.7 | 0.204 | 53,545.5 ± 98,390.1 | 103,803.3 ± 108,345.5 | 0.0001 |